Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

Patent metadata

Field	Value
Publication number	US-10596270-B2
Application number	US-201816133383-A
Country	US
Kind code	B2
Filing date	Sep 17, 2018
Priority date	Sep 18, 2017
Publication date	Mar 24, 2020
Grant date	Mar 24, 2020

Abstract

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

First claim

What is claimed is:

1. An antibody conjugate comprising an antibody that specifically binds to folate receptor alpha (FOLR1) linked site-specifically to at least one payload moiety, wherein the antibody comprises:
(i) a V H comprising: a CDR-H1 comprising one of SEQ ID NOs: 58 and 117; a CDR-H2 comprising one of SEQ ID NOs: 176 and 235; and a CDR-H3 comprising SEQ ID NO: 294; and
(ii) a V L comprising: a CDR-L1 comprising SEQ ID NO: 299; a CDR-L2 comprising SEQ ID NO: 302; and a CDR-L3 comprising SEQ ID NO: 305,
and wherein the antibody comprises one or more non-natural amino acids at sites selected from the group consisting of: HC-F404, HC-Y180, and LC-K42 according to the Kabat or EU numbering scheme of Kabat.

2. The antibody conjugate of claim 1 , wherein the one or more non-natural amino acids is selected from the group consisting of p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, an -3-(2-naphthyl)alanine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcβ-serine, L-Dopa, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-azido-methyl-L-phenylalanine, formula (30):

formula (56):

p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, L-phosphoserine, phosphonoserine, phosphonotyrosine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, and p-propargyloxy-phenylalanine.

3. The antibody conjugate of claim 1 , wherein a residue of the one or more non-natural amino acids is linked to the payload moiety via a linker that is cleavable.

4. The antibody conjugate of claim 2 , wherein the non-natural amino acid residue is a residue of formula (30):

or formula (56):

5. The antibody conjugate of claim 1 , wherein the payload moiety is selected from the group consisting of maytansines, hemiasterlins, amanitins, and auristatins.

6. The antibody conjugate of claim 1 , wherein the payload moiety is selected from the group consisting of DM1, hemiasterlin, amanitin, MMAF, and MMAE.

7. The antibody conjugate of claim 1 , wherein the antibody comprises a V H region comprising SEQ ID NO: 362, or a variant thereof having 7 or fewer amino acid substitutions, and a V L region comprising SEQ ID NO: 367, or a variant thereof having 7 or fewer amino acid substitutions.

8. The antibody of claim 7 , wherein the amino acid substitutions are conservative amino acid substitutions.

9. The antibody conjugate of claim 1 , wherein the antibody comprises a non-natural amino acid at site HC-F404.

10. The antibody conjugate of claim 1 , wherein the antibody comprises non-natural amino acids at sites HC-F404 and HC-Y180.

11. The antibody conjugate of claim 1 , wherein the antibody comprises non-natural amino acids at sites HC-F404 and LC-K42.

12. The antibody conjugate of claim 9 , wherein the non-natural amino acids are selected from the group consisting of para-azidomethylphenylalanine and p-azido-methyl-L-phenylalanine.

13. The antibody conjugate of claim 11 , wherein the non-natural amino acids are selected from the group consisting of para-azidomethylphenylalanine and para-azido-methyl-L-phenylalanine.

14. The antibody conjugate of claim 1 , wherein the antibody conjugate has the structure of Conjugate P:

wherein n is an integer from 1 to 6.

15. The antibody conjugate of claim 1 , wherein the antibody comprises a V H region comprising SEQ ID NO: 362, a V L region comprising SEQ ID NO: 367, a non-natural amino acid at each of sites HC-F404 and HC-Y180, wherein the non-natural amino acid is para-azidomethylphenylalanine, and wherein the antibody conjugate has the structure of Conjugate P:

wherein n is an integer from 1 to 4,
and wherein at least one bracketed structure is covalently bonded to the side chain of para-azidomethylphenylalanine at HC-F404 and at least one bracketed structure is covalently bonded to the side chain of para-azidomethylphenylalanine at HC-Y180.

16. The antibody conjugate of claim 1 , further comprising at least one constant region domain comprising a sequence selected from SEQ ID NOs: 370, 371, and 372.

17. The antibody conjugate of claim 1 , wherein the antibody is a monoclonal antibody selected from the group consisting of: an IgA, an IgD, an IgE, an IgG, and an IgM.

18. The antibody conjugate of claim 1 , wherein the antibody is humanized or human.

19. The antibody conjugate of claim 1 , wherein the antibody is aglycosylated.

20. The antibody conjugate of claim 1 , wherein the antibody is an antibody fragment selected from the group consisting of: an Fv fragment, a Fab fragment, a F(ab′) 2 fragment, a Fab′ fragment, an scFv (sFv) fragment, and an scFv-Fc fragment.

21. A pharmaceutical composition comprising the antibody conjugate of claim 1 and a pharmaceutically acceptable carrier.

22. A method of treating a cancer that overexpresses folate receptor alpha, comprising administering to the subject an effective amount of an antibody conjugate of claim 1 .

23. A method of treating a cancer that overexpresses folate receptor alpha, comprising administering to the subject an effective amount of, or a pharmaceutical composition of claim 21 .

24. The method of claim 22 , wherein the cancer is selected from the group consisting of: triple-negative breast cancer (TNBC), ovarian cancer, and endometrial cancer.

Assignees

• Sutro Biopharma Inc

Inventors

• Stafford Ryan
• Yam Alice
• Li Xiaofan
• Yin Gang
• Kline Toni
• Abrahams Cristina
• De Almeida Venita

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61K47/6849 Primary

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6889

  Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment · CPC title

• A61K47/6811

  the drug being a protein or peptide, e.g. transferrin or bleomycin · CPC title